Wilmer Cutler Pickering Hale and Dorr represented Arbor Biotechnologies in the transaction. Arbor Biotechnologies announced a strategic partnership with 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT). As part of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Air Space Intelligence in the transaction. Air Space Intelligence (ASI) announced the completion of a $34 million Series B funding round....
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler advised Celldex Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Celldex Therapeutics, Inc. (Nasdaq: CLDX) (“Celldex”) announced the...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Arvinas, Inc. on the transaction. Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas”) announced that it entered into a securities purchase agreement with a...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented State Street Corporation in the offering, and Cravath, Swaine & Moore represented the underwriters. State Street Corporation (NYSE: STT)...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Depository Trust & Clearing Corporation in the transaction. Fnality announced it has secured £77.7M (approximately $97.39 million) in Series B...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr is representing WEX in the transaction. WEX (NYSE: WEX) announced the signing of a definitive agreement to acquire Payzer. Pursuant to...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr is advising Aleph on the transaction. Aleph announced its Series A financing round as it emerged from stealth mode. The round was...
You must be a Standard 1 Year member to access this content.
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented HawkEye 360, Inc. in the transaction. HawkEye 360, Inc. announced the subsequent closing of its Series D-1 Preferred Stock financing, which was...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented MKS Instruments, Inc. in the deal. MKS Instruments, Inc. (NASDAQ:MKSI) announced the repricing of its existing $3.6 billion secured tranche...
You must be a Standard 1 Year member to access this content.
